Page last updated: 2024-11-05

phloroglucinol dimethyl ether

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

phloroglucinol dimethyl ether: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10383
CHEMBL ID462989
CHEBI ID88715
SCHEMBL ID233829
MeSH IDM0064223

Synonyms (42)

Synonym
einecs 207-917-7
unii-23uxw8136a
nsc 70955
23uxw8136a ,
phenol, 3,5-dimethoxy-
500-99-2
3,5-dimethoxyphenol
taxicatigenin
phenol,5-dimethoxy-
1-hydroxy-3,5-dimethoxybenzene
nsc-70955
nsc70955
phloroglucinol dimethyl ether
3,5-dimethoxyphenol, 99%
inchi=1/c8h10o3/c1-10-7-3-6(9)4-8(5-7)11-2/h3-5,9h,1-2h
AC-11324
P0320
HMS1715K12
chebi:88715 ,
CHEMBL462989
AKOS000121581
A827974
FT-0614645
S6071
SCHEMBL233829
AM83169
3,5-dimethoxy-phenol
3,5-dimethoxy phenol
W-105986
STR06179
mfcd00008388
DTXSID7075426
F0001-1304
CS-W001117
F17066
Z56347218
STL554909
Q27160623
BBL101113
SY035504
HY-W001117
EN300-16614
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
methoxybenzenesAny aromatic ether that consists of a benzene skeleton substituted with one or more methoxy groups.
phenolsOrganic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
1,3,5-trimethoxybenzene biosynthesis57
1,3,5-trimethoxybenzene biosynthesis67

Bioassays (5)

Assay IDTitleYearJournalArticle
AID1594775Protection against AfB1-induced toxicity in human HepG2 cells assessed as live cell area at 5 uM measured after 48 hrs by calcein-AM/Hoechst 33342 staining based high-content imaging analysis relative to control2019Journal of natural products, 06-28, Volume: 82, Issue:6
Natural-Product-Inspired Compounds as Countermeasures against the Liver Carcinogen Aflatoxin B
AID1594778Protection against AfB1-induced toxicity in human HepG2 cells assessed as increase in live cell area at >5 uM measured after 48 hrs by calcein-AM/Hoechst 33342 staining based high-content imaging analysis relative to control2019Journal of natural products, 06-28, Volume: 82, Issue:6
Natural-Product-Inspired Compounds as Countermeasures against the Liver Carcinogen Aflatoxin B
AID346025Binding affinity to beta cyclodextrin2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Convenient QSAR model for predicting the complexation of structurally diverse compounds with beta-cyclodextrins.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (6.25)18.2507
2000's4 (25.00)29.6817
2010's9 (56.25)24.3611
2020's2 (12.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.25

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.25 (24.57)
Research Supply Index3.00 (2.92)
Research Growth Index5.25 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.25)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies8 (42.11%)4.05%
Observational0 (0.00%)0.25%
Other11 (57.89%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]